On June 27, 2026, Cefixim 200, a product of Cuu Long Pharmaceutical Joint Stock Company (DCL), was honored as one of the Top 10 Consumer-Oriented Products of 2026. The award was presented as part of a program jointly organized by the Institute for Development Issues, the Institute of Economics and Culture, and the Vietnam Consumer Protection Center to recognize products that demonstrate outstanding quality, deliver tangible value, and prioritize consumer interests.
The recognition of Cefixim 200 reflects DCL’s continuous commitment to researching, manufacturing, and supplying high-quality pharmaceutical products that meet the growing healthcare needs of the community. It also reinforces the company’s long-standing development philosophy of placing product quality and consumer well-being at the center of its business strategy.
Mr. Pham Chung Dinh, Deputy Chief Executive Officer for Sales of Cuu Long Pharmaceutical Joint Stock Company, receives the Top 10 Consumer-Oriented Products of 2026 award.
As one of DCL’s key pharmaceutical products, Cefixim 200 is manufactured using modern production lines and in strict compliance with pharmaceutical quality management standards. Throughout the product development process, DCL carefully controls every stage—from raw material selection and manufacturing to quality testing—to ensure that every product delivered to patients meets rigorous standards of quality, safety, and effectiveness.
Beyond investing in advanced manufacturing technologies, DCL continuously improves its products, strengthens its quality management capabilities, and optimizes operational processes. The company believes that as the pharmaceutical industry evolves and consumer expectations continue to rise, delivering safe, reliable, and high-quality medicines remains the cornerstone of building a trusted and sustainable brand.
Speaking about this achievement, Mr. Pham Chung Dinh said: “The recognition of Cefixim 200 is a source of great pride for the entire DCL team and reflects our ongoing commitment to improving product quality. For us, every product must not only meet manufacturing standards but also deliver real value to the people who use it. DCL will continue investing in technology, research and development, and quality management systems to provide more safe and effective pharmaceutical products, contributing to better community healthcare and enhancing the reputation of Vietnamese pharmaceuticals.”
Mr. Pham Chung Dinh shares his remarks at the award ceremony.
As part of its long-term development strategy, DCL has identified technological innovation and investment in research and product development as key strategic pillars. The company continues to implement major investment projects aimed at expanding its manufacturing capabilities, meeting international quality standards, and strengthening its competitiveness in both domestic and global markets.
The recognition of Cefixim 200 as one of the Top 10 Consumer-Oriented Products of 2026 not only acknowledges the excellence of a single product but also reflects DCL’s enduring commitment to creating sustainable value for consumers. Backed by 50 years of development, an experienced workforce, and a well-defined investment strategy, DCL remains dedicated to delivering high-quality pharmaceutical products that protect public health while strengthening consumer confidence in Vietnamese pharmaceutical brands.
